Form 8-K · Current Report · Filed 2025-09-19
Hologic, Inc. Extends CEO's Employment Agreement
On September 18, 2025, Hologic, Inc. announced an amendment to the employment agreement of Stephen P. MacMillan, its Chairman, President, and Chief Executive Officer, extending the term of the agreement until it is terminated by either party in accordance with its terms.
- Filer
- Hologic Inc. HOLX · NASDAQ
- Filed
- Accession
- 0001140361-25-035568
- CIK
- 0000859737
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Market reaction
Close before filing
$68.27
Next session
-1.4%
Since filing
+11.3%
Latest close
$76.01
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HOLX reporting the same item, with the next session's move:
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Never miss another HOLX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.